Nisoldipine: a new dihydropyridine calcium-channel blocker

¹Department of Medicine, Albert Einstein College of Medicine, Bronx, New York.

|January 1, 1993

Abstract:

Nisoldipine is a new calcium-channel blocker of the dihydropyridine subclass, with a chemical structure similar to nifedipine. It has been used in clinical trials to assess its efficacy and safety in patients with hypertension, angina pectoris, and congestive heart failure. Similar to other dihydropyridines, nisoldipine is a potent peripheral and coronary dilator. The most optimal dosage regimen has not been established in clinical trials. The drug appears to have a favorable side-effect profile.

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Transverse-momentum and collision-energy dependence of high-pT hadron suppression in Au+Au collisions at ultrarelativistic energies.

Physical review letters·2003

Related Experiment Videos

Nisoldipine: a new dihydropyridine calcium-channel blocker

Related Concept Videos

Transverse-momentum and collision-energy dependence of high-pT hadron suppression in Au+Au collisions at ultrarelativistic energies.

Measurements of GnE/GnM from the 2H(e-->,en-->)1H Reaction to Q2=1.45 (GeV/c)2.

Long-term blockade of nitric oxide synthesis in rats modulates coronary capillary network remodeling.

Evidence from d+Au measurements for final-state suppression of high-p(T) hadrons in Au+Au collisions at RHIC.

Cross-section measurement of charged-pion photoproduction from hydrogen and deuterium.

Pore surface exploration by NMR.

Long-Acting Injectable Antiretroviral Therapies for HIV Treatment and Prevention: Clinical Pharmacology, Recent Advances and Future Opportunities.

Clinical Pharmacology of Eplontersen, the First Approved GalNAc-Conjugated Antisense Oligonucleotide.

Pharmacokinetic/Pharmacodynamic Translation and Model-Informed Drug Development for Oligonucleotide Therapeutics.

Application of Model-Informed Approaches in Neuroscience Drug Development and Regulatory Decision-Making.

First-In-Human Evaluation of the Pharmacokinetics, Pharmacodynamics, and Safety of Tilpisertib Fosmecarbil (GS-5290), an Oral Prodrug of a Tumor Progression Locus 2 Inhibitor in Healthy Participants.

A Review of Semi-Mechanistic HbA1c Models in People with Type 2 Diabetes: Strengths, Limitations, and Applications.

Macrolide-Induced Aldosterone Suppression as a Functional Marker of KCNJ5-Mutated Aldosterone-Producing Adenoma: A Proof-of-Concept Clinical and Experimental Study (MAPA Study).

Related Experiment Videos

Nisoldipine: a new dihydropyridine calcium-channel blocker

Abstract:

Related Concept Videos

Related Articles